BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24670134)

  • 1. Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients.
    Kang EH; Kuwana M; Okazaki Y; Lee EY; Lee YJ; Lee EB; Song YW
    Mod Rheumatol; 2014 Nov; 24(6):945-8. PubMed ID: 24670134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis.
    Kang EH; Nakashima R; Mimori T; Kim J; Lee YJ; Lee EB; Song YW
    BMC Musculoskelet Disord; 2010 Sep; 11():223. PubMed ID: 20875136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
    Fiorentino DF; Chung LS; Christopher-Stine L; Zaba L; Li S; Mammen AL; Rosen A; Casciola-Rosen L
    Arthritis Rheum; 2013 Nov; 65(11):2954-62. PubMed ID: 24037894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.
    Sato S; Murakami A; Kuwajima A; Takehara K; Mimori T; Kawakami A; Mishima M; Suda T; Seishima M; Fujimoto M; Kuwana M
    PLoS One; 2016; 11(4):e0154285. PubMed ID: 27115353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
    Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
    Fujimoto M; Hamaguchi Y; Kaji K; Matsushita T; Ichimura Y; Kodera M; Ishiguro N; Ueda-Hayakawa I; Asano Y; Ogawa F; Fujikawa K; Miyagi T; Mabuchi E; Hirose K; Akimoto N; Hatta N; Tsutsui K; Higashi A; Igarashi A; Seishima M; Hasegawa M; Takehara K
    Arthritis Rheum; 2012 Feb; 64(2):513-22. PubMed ID: 21987216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
    Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
    Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.
    Fiorentino DF; Kuo K; Chung L; Zaba L; Li S; Casciola-Rosen L
    J Am Acad Dermatol; 2015 Mar; 72(3):449-55. PubMed ID: 25595720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
    Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
    Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting.
    Kuwana M; Okazaki Y
    Mod Rheumatol; 2023 Apr; 33(3):543-548. PubMed ID: 35662349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays.
    Labrador-Horrillo M; Martínez MA; Selva-O'Callaghan A; Trallero-Araguás E; Balada E; Vilardell-Tarrés M; Juarez C
    Ann Rheum Dis; 2012 Jun; 71(6):993-6. PubMed ID: 22294626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.
    Ceribelli A; Fredi M; Taraborelli M; Cavazzana I; Tincani A; Selmi C; Chan JY; Chan EK; Satoh M; Franceschini F
    Clin Exp Rheumatol; 2014; 32(6):891-7. PubMed ID: 25151986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2.
    Ishikawa A; Muro Y; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Jul; 51(7):1181-7. PubMed ID: 22427409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.
    Satoh M; Tanaka S; Ceribelli A; Calise SJ; Chan EK
    Clin Rev Allergy Immunol; 2017 Feb; 52(1):1-19. PubMed ID: 26424665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapidly progressive interstitial lung disease combined with pneumocystis jiroveci pneumonia in a patient with single anti-TIF-1γ antibody positive dermatomyositis in the context of an underlying tumor.
    Zhang H; Yue J; Hou X; Lu H; Bikdeli A; Guo H; Li H; Li D
    BMC Pulm Med; 2023 Jul; 23(1):248. PubMed ID: 37415133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM.
    Koga T; Fujikawa K; Horai Y; Okada A; Kawashiri SY; Iwamoto N; Suzuki T; Nakashima Y; Tamai M; Arima K; Yamasaki S; Nakamura H; Origuchi T; Hamaguchi Y; Fujimoto M; Ishimatsu Y; Mukae H; Kuwana M; Kohno S; Eguchi K; Aoyagi K; Kawakami A
    Rheumatology (Oxford); 2012 Jul; 51(7):1278-84. PubMed ID: 22378718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum B-cell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease.
    Matsushita T; Kobayashi T; Kano M; Hamaguchi Y; Takehara K
    J Dermatol; 2019 Dec; 46(12):1190-1196. PubMed ID: 31631384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.